DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans
by Zacks Equity Research
Accuray's (ARAY) latest offering is likely to improve radiation treatment.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.
Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes
by Zacks Equity Research
Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.
Top Medical Stocks to Buy Amid Market Volatility
by Shaun Pruitt
While there is no guarantee that medical stocks will offer a hedge against market volatility, healthcare is essential even during economic uncertainty.
Here's Why You Should Retain Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab's (ECL) strength in its business raises optimism about the stock.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) on strong global expansion.
Buy These 3 Low-Beta Stocks to Navigate Volatility
by Derek Lewis
Adding low-beta stocks can be a great way to counter volatility, as these stocks are less sensitive to the market's overall movements
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
NextGen (NXGN) Extends Agreement to Boost Athletico's Footprint
by Zacks Equity Research
NextGen's (NXGN) latest extended agreement is likely to reflect its solutions' potential to aid healthcare organizations at all stages of growth.
Here's Why Investors Should Invest in Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.
QIAGEN (QGEN) Extends QIAwave Product Line With New Kit
by Zacks Equity Research
QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.
3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical
by Zacks Equity Research
Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.
3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like GIII, CEG, CWCO and DVA that are seeing price strength have a high chance of carrying the momentum forward.
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and McKesson (MCK) have performed compared to their sector so far this year.
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.